Published in Lab Invest on May 01, 2003
Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev (2008) 10.28
Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology (2009) 4.82
Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest (2007) 4.41
Cellular and molecular mechanisms of liver injury. Gastroenterology (2008) 3.02
Apoptosis: a mechanism of acute and chronic liver injury. Gut (2005) 2.33
Hepatocyte death: a clear and present danger. Physiol Rev (2010) 2.18
From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol (2013) 1.75
Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology (2014) 1.73
Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J Clin Invest (2003) 1.73
Hepatic inflammation and fibrosis: functional links and key pathways. Hepatology (2015) 1.68
Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol (2007) 1.59
Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology (2009) 1.55
TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse. Hepatology (2008) 1.45
Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice. J Clin Invest (2011) 1.42
Leptin promotes the myofibroblastic phenotype in hepatic stellate cells by activating the hedgehog pathway. J Biol Chem (2010) 1.33
Activation of hepatic stellate cells after phagocytosis of lymphocytes: A novel pathway of fibrogenesis. Hepatology (2008) 1.31
Redox mechanisms in hepatic chronic wound healing and fibrogenesis. Fibrogenesis Tissue Repair (2008) 1.30
NOX in liver fibrosis. Arch Biochem Biophys (2007) 1.29
Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies. J Gastroenterol (2008) 1.23
Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. Expert Rev Gastroenterol Hepatol (2011) 1.22
Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options. Comp Hepatol (2007) 1.22
Apoptosis as a mechanism for liver disease progression. Semin Liver Dis (2010) 1.21
Apoptosis and cytokines in non-alcoholic steatohepatitis. Clin Liver Dis (2009) 1.21
Apoptotic body engulfment by hepatic stellate cells promotes their survival by the JAK/STAT and Akt/NF-kappaB-dependent pathways. J Hepatol (2009) 1.17
Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis. Am J Physiol Gastrointest Liver Physiol (2010) 1.17
Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral Res (2014) 1.17
Advances in antifibrotic therapy. Expert Rev Gastroenterol Hepatol (2008) 1.17
HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol (2014) 1.16
NADPH oxidase mediated oxidative stress in hepatic fibrogenesis. Korean J Hepatol (2011) 1.13
A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology (2011) 1.12
Role of NADPH oxidases in liver fibrosis. Antioxid Redox Signal (2014) 1.10
Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology (2012) 1.09
Cell death and fibrogenesis. Semin Liver Dis (2010) 1.09
Effect of intracellular lipid accumulation in a new model of non-alcoholic fatty liver disease. BMC Gastroenterol (2012) 1.09
Role and cellular source of nicotinamide adenine dinucleotide phosphate oxidase in hepatic fibrosis. Hepatology (2010) 1.08
Death Receptor-Mediated Cell Death and Proinflammatory Signaling in Nonalcoholic Steatohepatitis. Cell Mol Gastroenterol Hepatol (2015) 1.06
Apoptosis and necrosis in the liver. Compr Physiol (2013) 1.05
Liver sinusoidal endothelial cells in hepatic fibrosis. Hepatology (2015) 1.05
Leptin induces phagocytosis of apoptotic bodies by hepatic stellate cells via a Rho guanosine triphosphatase-dependent mechanism. Hepatology (2008) 1.05
Mechanisms of pancreatic fibrosis and applications to the treatment of chronic pancreatitis. J Gastroenterol (2008) 1.05
Succinate is a paracrine signal for liver damage. J Hepatol (2007) 1.04
Mechanisms and biomarkers of apoptosis in liver disease and fibrosis. Int J Hepatol (2012) 1.02
Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci (2014) 1.00
Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update. World J Gastroenterol (2014) 0.97
Hepatitis C virus and cellular stress response: implications to molecular pathogenesis of liver diseases. Viruses (2012) 0.97
Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease. J Appl Physiol (1985) (2012) 0.96
In vitro and in vivo protection of stellate cells from apoptosis by leptin. Dig Dis Sci (2006) 0.94
NIM811 (N-methyl-4-isoleucine cyclosporine), a mitochondrial permeability transition inhibitor, attenuates cholestatic liver injury but not fibrosis in mice. J Pharmacol Exp Ther (2008) 0.93
Pancreatic stellate cells express Toll-like receptors. J Gastroenterol (2008) 0.93
Bioconjugation of oligonucleotides for treating liver fibrosis. Oligonucleotides (2007) 0.88
Cellular and molecular functions of hepatic stellate cells in inflammatory responses and liver immunology. Hepatobiliary Surg Nutr (2014) 0.88
Liver fibrosis and protection mechanisms action of medicinal plants targeting apoptosis of hepatocytes and hepatic stellate cells. Adv Pharmacol Sci (2014) 0.86
Targeting the tumor stroma in hepatocellular carcinoma. World J Hepatol (2015) 0.86
Macrophage migration inhibitory factor is required for recruitment of scar-associated macrophages during liver fibrosis. J Leukoc Biol (2014) 0.86
Hepatocyte apoptotic bodies encasing nonstructural HCV proteins amplify hepatic stellate cell activation: implications for chronic hepatitis C. J Viral Hepat (2010) 0.85
Activation of Mir-29a in Activated Hepatic Stellate Cells Modulates Its Profibrogenic Phenotype through Inhibition of Histone Deacetylases 4. PLoS One (2015) 0.85
The coagulation factor Xa/protease activated receptor-2 axis in the progression of liver fibrosis: a multifaceted paradigm. J Cell Mol Med (2009) 0.83
Caspase inhibitors for the treatment of hepatitis C. Clin Liver Dis (2009) 0.82
TLRs in Hepatic Cellular Crosstalk. Gastroenterol Res Pract (2010) 0.82
Aliskiren attenuates steatohepatitis and increases turnover of hepatic fat in mice fed with a methionine and choline deficient diet. PLoS One (2013) 0.81
Plasma gelsolin protein: a candidate biomarker for hepatitis B-associated liver cirrhosis identified by proteomic approach. Blood Transfus (2010) 0.81
Targeting Hepatic Fibrosis in Autoimmune Hepatitis. Dig Dis Sci (2016) 0.81
Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies. Clin Gastroenterol Hepatol (2013) 0.80
M1 Muscarinic Receptor Deficiency Attenuates Azoxymethane-Induced Chronic Liver Injury in Mice. Sci Rep (2015) 0.80
Targeting apoptosis in autoimmune hepatitis. Dig Dis Sci (2014) 0.80
An algorithm that predicts the viability and the yield of human hepatocytes isolated from remnant liver pieces obtained from liver resections. PLoS One (2014) 0.80
Pathophysiological Significance of Hepatic Apoptosis. ISRN Hepatol (2012) 0.79
Overexpression of mcl-1 attenuates liver injury and fibrosis in the bile duct-ligated mouse. Dig Dis Sci (2008) 0.78
Adverse outcome pathway development from protein alkylation to liver fibrosis. Arch Toxicol (2016) 0.77
Ursodeoxycholyl lysophosphatidylethanolamide attenuates hepatofibrogenesis by impairment of TGF-β1/Smad2/3 signalling. Br J Pharmacol (2014) 0.77
IGFBPrP1 induces liver fibrosis by inducing hepatic stellate cell activation and hepatocyte apoptosis via Smad2/3 signaling. World J Gastroenterol (2014) 0.77
Inflammatory Gene Expression Upon TGF-β1-Induced p38 Activation in Primary Dupuytren's Disease Fibroblasts. Front Mol Biosci (2015) 0.77
Effects of cell-type-specific expression of a pan-caspase inhibitor on renal fibrogenesis. Clin Exp Nephrol (2014) 0.76
MicroRNA-34a Negatively Regulates Efferocytosis by Tissue Macrophages in Part via SIRT1. J Immunol (2015) 0.76
Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis. Semin Liver Dis (2016) 0.76
Rutin Attenuates Hepatotoxicity in High-Cholesterol-Diet-Fed Rats. Oxid Med Cell Longev (2016) 0.75
Hepatitis C Virus Infection of Cultured Human Hepatoma Cells Causes Apoptosis and Pyroptosis in Both Infected and Bystander Cells. Sci Rep (2016) 0.75
Enhanced apoptosis in post-liver transplant hepatitis C: effects of virus and immunosuppressants. World J Gastroenterol (2012) 0.75
Apoptosis induced by Fas signaling does not alter hepatic hepcidin expression. World J Biol Chem (2014) 0.75
HIV-1 tropism and liver fibrosis in HIV-HCV co-infected patients. PLoS One (2012) 0.75
Effect of Immunosuppressive Agents on Hepatocyte Apoptosis Post-Liver Transplantation. PLoS One (2015) 0.75
New Concepts on Pathogenesis and Diagnosis of Liver Fibrosis; A Review Article. Middle East J Dig Dis (2016) 0.75
Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol (2017) 0.75
Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the Abcb4(-/-) mouse model. World J Hepatol (2016) 0.75
Fas Regulates Macrophage Polarization and Fibrogenic Phenotype in a Model of Chronic Ethanol-Induced Hepatocellular Injury. Am J Pathol (2016) 0.75
Baicalin Ameliorates Experimental Liver Cholestasis in Mice by Modulation of Oxidative Stress, Inflammation, and NRF2 Transcription Factor. Oxid Med Cell Longev (2017) 0.75
Protective effect of human serum amyloid P on CCl4-induced acute liver injury in mice. Int J Mol Med (2017) 0.75
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84
Mechanisms of hepatotoxicity. Toxicol Sci (2002) 4.13
Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology (2008) 3.95
Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85
Diagnosis and management of primary sclerosing cholangitis. Hepatology (2010) 3.60
Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem (2006) 3.57
Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology (2006) 3.52
Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol (2011) 3.36
Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology (2004) 3.23
Cholangiocarcinoma. Gastroenterology (2005) 3.15
Cellular and molecular mechanisms of liver injury. Gastroenterology (2008) 3.02
Lysosomes in cell death. Oncogene (2004) 3.00
Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis (2008) 2.89
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene (2005) 2.89
Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology (2013) 2.81
Apoptosis: the nexus of liver injury and fibrosis. Hepatology (2004) 2.70
Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology (2010) 2.68
Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation. Liver Transpl (2015) 2.63
EUS-guided FNA of regional lymph nodes in patients with unresectable hilar cholangiocarcinoma. Gastrointest Endosc (2007) 2.61
Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest (2012) 2.56
Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol (2011) 2.51
Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology (2003) 2.45
Life and death by death receptors. FASEB J (2009) 2.39
Cholangiocarcinoma. Clin Liver Dis (2008) 2.33
Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology (2012) 2.33
Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest (2014) 2.31
Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol (2003) 2.29
Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-vascular loop. Arterioscler Thromb Vasc Biol (2008) 2.29
Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg (2005) 2.23
A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol (2004) 2.23
MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology (2009) 2.23
Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol (2006) 2.19
Hepatocyte death: a clear and present danger. Physiol Rev (2010) 2.18
Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis (2005) 2.18
A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology (2007) 2.16
Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest (2006) 2.03
Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology (2005) 2.03
Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. J Biol Chem (2007) 2.01
Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology (2011) 2.01
Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut (2007) 1.99
Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology (2002) 1.98
Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. J Clin Invest (2010) 1.97
Deaths on the liver transplant waiting list: an analysis of competing risks. Hepatology (2006) 1.93
Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res (2004) 1.91
The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology (2008) 1.88
Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology (2003) 1.86
A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol (2004) 1.83
JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem (2009) 1.82
Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol (2004) 1.80
Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology (2005) 1.78
Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J Clin Invest (2003) 1.73
Amelioration of hepatic fibrosis by NK cell activation. Gut (2010) 1.71
Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology (2012) 1.70
Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology (2006) 1.68
De novo nonalcoholic fatty liver disease after liver transplantation. Liver Transpl (2007) 1.68
A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. Clin Gastroenterol Hepatol (2004) 1.66
Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am J Physiol Gastrointest Liver Physiol (2006) 1.66
A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology (2008) 1.65
Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Int J Med Microbiol (2007) 1.65
Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma. Liver Transpl (2007) 1.64
Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. J Biol Chem (2007) 1.63
Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci (2005) 1.63
The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci (2005) 1.63
Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology (2006) 1.60
The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther (2003) 1.60
Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology (2013) 1.58
Liver transplantation for cholangiocarcinoma. Transpl Int (2010) 1.58
Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. J Hepatol (2010) 1.56
Apoptosis and cellular activation in the pathogenesis of acute vascular rejection. Circ Res (2002) 1.56
Innate immunity in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol (2011) 1.55
Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology (2009) 1.55
Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol (2012) 1.55
CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis. Am J Physiol Gastrointest Liver Physiol (2010) 1.54
Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination. HPB (Oxford) (2011) 1.54
Octreotide therapy for advanced hepatocellular carcinoma. J Clin Gastroenterol (2005) 1.53
Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology (2010) 1.53
IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. Hepatology (2015) 1.52
"Will all liver transplantation patients eventually die from cancer?". J Hepatol (2005) 1.52
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol (2012) 1.51
Caveolin-1 can regulate vascular smooth muscle cell fate by switching platelet-derived growth factor signaling from a proliferative to an apoptotic pathway. Arterioscler Thromb Vasc Biol (2003) 1.50
Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology (2009) 1.49
Bile acids activate EGF receptor via a TGF-alpha-dependent mechanism in human cholangiocyte cell lines. Am J Physiol Gastrointest Liver Physiol (2003) 1.48
Tumor necrosis factor-alpha-associated lysosomal permeabilization is cathepsin B dependent. Am J Physiol Gastrointest Liver Physiol (2002) 1.47
The emergence of a new discipline, hepatobiliary oncology. Hepatology (2008) 1.46
TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse. Hepatology (2008) 1.45
Tumor necrosis factor-related apoptosis-inducing ligand activates a lysosomal pathway of apoptosis that is regulated by Bcl-2 proteins. J Biol Chem (2007) 1.43
Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol (2005) 1.43